Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Germline variants drive myelodysplastic syndrome in young adults

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Incidence and variation in age of onset by causal gene.


  1. Churpek JE, Pyrtel K, Kanchi K-L, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126:2484–90.

    Article  CAS  Google Scholar 

  2. Guidugli L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, Arndt K, Churpek JE, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017;31:1226–9.

    Article  CAS  Google Scholar 

  3. Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica. 2016;101:1343–50.

    Article  CAS  Google Scholar 

  4. Peterson LC, Bloomfield CD, Niemeyer CM, Döhner HGL. Myeloid neoplasms with germline predisposition. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th ed) Lyon, IARC. 2017.

  5. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  6. Ghemlas I, Li H, Zlateska B, Klaassen R, Fernandez CV, Yanofsky RA, et al. Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. J Med Genet. 2015;52:575–84.

    Article  CAS  Google Scholar 

  7. Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun. 2017;8:1557.

    Article  Google Scholar 

  8. Wlodarski MW, Hirabayashi S, Pastor V, Starý J, Hasle H, Masetti R, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387–97.

    Article  CAS  Google Scholar 

  9. Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134:1441–4.

    Article  Google Scholar 

  10. Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102:1683–90.

    Article  Google Scholar 

  11. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Cancer. 2007;109:1536–42.

    Article  Google Scholar 

  12. Trottier AM, Druhan LJ, Kraft IL, Lance A, Feurstein S, Helgeson M, et al. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Adv. 2020;4:5269–84.

    Article  Google Scholar 

  13. Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125:591–9.

    Article  CAS  Google Scholar 

  14. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transpl. 2011;46:98–104.

    Article  CAS  Google Scholar 

  15. Ebens CL, MacMillan ML, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol 2017;10:81–97.

    Article  CAS  Google Scholar 

Download references


The authors would like to gratefully acknowledge all of the individuals who participated in this study and their physicians for submitting the clinical samples. We would also like to thank Michelle Le Beau and Ludmila Hill from the Cancer Cytogenetics Laboratory at The University of Chicago for providing viably frozen bone marrow samples. This study was supported by the Cancer Research Foundation and the Taub Foundation (L.A.G.), the intramural ‘Baustein’ program for Junior Scientists of the Medical Faculty of Ulm University, Ulm, Germany (S.F.), and the German Bundesministerium für Bildung und Forschung ‘MyPred’ (01GM1911B) (B.S., G.G.) and ‘ADDRess’ (01GM1909A) (G.G.) and the Cancer Society of Finland, the Children’s Cancer Foundation Väre, and the Sigrid Juselius Foundation (M.H., O.K., U.W-K.). In addition, the NIH supported this work through: P30CA016056 (use of Roswell Park Comprehensive Cancer Center’s Hematologic Procurement Shared Resource, E.W.), R03HL145253 (J.E.C.), R35CA197458 and R24DK099808 (M-C.K., T.W., S.G., M.L.). We would also like to acknowledge the input of Linda Lutgen-Dunckley, Brandon Martens, and Joseph Moberg from the Roswell Park Hematologic Procurement Shared Resource (CIC 98-05) for providing samples supported by the Cancer Center Support Grant at Roswell Park (2P30CA016056-42). M-C.K. is an American Cancer Society Professor.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Lucy A. Godley.

Ethics declarations

Conflict of interest

We declare the following conflicts of interest: TW consults for Color Genomics. TH is part owner of the Munich Leukemia Laboratory. EAG has received honoraria/advisory board payments from Alexion Pharmaceuticals, Celgene/BMS, AbbVie, and Novartis. EAG has also received institutional research funding from Genentech Inc., Appelis pharmaceuticals, Celldex Therapeutics, and Celgene/BMS. CO has received honoraria/advisory board payments from AbbVie, AstraZeneca, Janssen, Roche, and Novartis. LAG and JEC have received honoraria from UptoDate, Inc. LAG has received advisory board payments from Invitae, Inc.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feurstein, S., Churpek, J.E., Walsh, T. et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia 35, 2439–2444 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links